I really don't get the current SP. When it was 8cps the company had hardly any cash left, needed to raise money imminently and was still trading significantly above cash backing. Today we have plenty of cash at hand and won't need to raise for some time (Q we all know about the options and CN's) yet are trading only just above cash backing. The review had some trial changes which will streamline the trials a bit, and save some time and money. I didn't think the review was overly negative as the SP is suggesting, indeed I would have thought that all the negativity was already baked into the SP before today. The only thing that I can really think of as driving the SP down at the moment is the 12.5c options and holders selling so they can cover themselves but the volume traded is insufficient for all of them to be doing that. If it keeps dropping I'll have to find some cash somewhere.
- Forums
- ASX - By Stock
- KZA
- Ann: Novogen Announces Outcome of Comprehensive Science Review
Ann: Novogen Announces Outcome of Comprehensive Science Review, page-54
-
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)